MOUNTAIN VIEW, Calif., July 19 /PRNewswire/ -- MAP Pharmaceuticals, a leading developer of novel inhaled drug products, today announced the appointment of Scott W. Borland to the position of Tempo(TM) DHE Program Director. MAP Pharmaceuticals also announced the appointment of Paul S. Uster to the position of Unit Dose Budesonide Program Director.
Mr. Borland is responsible for directing the company’s drug delivery product development, as well as Tempo platform engineering and manufacturing. Additionally, Mr. Borland is responsible for all development activities related to one of MAP’s lead products, a novel inhaled drug formulation of dihydroergotamine mesylate (DHE) administered with MAP’s patented Tempo Inhaler. Mr. Borland brings more than 12 years of technology development, product development, and process engineering experience to MAP. Prior to joining the company, he held several key management positions at Capnia Inc. and Aerogen Inc., including Vice President of Engineering and Senior Director, Engineering and Operations. In these roles, Mr. Borland was responsible for design engineering and manufacturing of technology components and systems for aerosol-based pulmonary drug delivery and medical gas delivery products. In addition, he was instrumental in regulatory activities and manufacturing scale-up of both clinical and commercially marketed products.
“Scott combines a broad set of skills critical to the development and launch of the MAP delivery platform,” said Thomas A. Armer, Chief Scientific Officer of MAP. “He joins us as our Phase 2 clinical trials are beginning and will have a significant impact on the development of the Tempo platform and the design of MAP’s first commercial product. Scott will also play a key role in our other product research and development plans as well as the growth of our pulmonary-based product pipeline.”
Mr. Borland has held several other positions in the medical device, drug delivery, and computer hardware industries with Therics, Inc., Topaz Technologies, and Applied Magnetics and was previously a Visiting Scientist at the Massachusetts Institute of Technology. Mr. Borland holds an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and a B.S. in Materials Science and Engineering from the University of Arizona.
Dr. Uster is responsible for all development activities related to another MAP lead product candidate, Unit Dose Budesonide. Dr. Uster brings with him more than 20 years of experience in the pharmaceutical development field with a specific focus in the areas of novel technology and drug development and post market development. Dr. Uster’s expertise includes an in-depth knowledge of the requirements and processes for pulmonary product approval, including the requirements of combination drug/device products. Prior to joining the company, he held key management positions at Peninsula Pharmaceuticals, Aerogen Inc., and SEQUUS Pharmaceuticals, Inc. Such positions included Senior Director of Product Development, Pharmaceutics, Formulation Development, and Director of Medical Affairs. In these roles, Dr. Uster directed the commercial pharmaceutical development process and managed strategic partnerships, in addition to continuing his extensive work with drug and device development.
“Paul’s impressive breadth of experience in all areas of pharmaceutical development will greatly contribute to the advancement of the Unit Dose Budesonide program,” said Dr. Armer. “As we continue to aggressively accelerate this program, Paul’s experience and in-depth knowledge of current developments in the field will prove extremely valuable as we move the company toward commercialization of our products.”
Prior to joining the pharmaceutical industry, Dr. Uster was a Carnegie Fellow at Johns Hopkins University. Dr. Uster holds a Ph.D. in Molecular and Cellular Biology from the University of California, Davis and a B.A. in Biology from the University of California, San Diego.
“I am delighted that we have two highly qualified and experienced individuals ready to step in and assume these new roles,” said Timothy S. Nelson, CEO of MAP Pharmaceuticals. “We remain focused on realizing our mission of helping a large population of patients that are currently underserved,” Nelson noted. “As we broaden our scope of therapeutic opportunities, Scott’s and Paul’s roles will be to ensure that our technology and drug development continues to grow with us. We are fortunate to have them in these key positions.”
About Tempo(TM) Inhaler
MAP’s Tempo(TM) Inhaler is a proprietary, breath synchronized plume controlled inhaler. The Tempo Inhaler automatically adjusts to each patient’s unique inspiration pattern, without electronics, and is exceptionally easy to use, enhancing compliance. The Tempo Inhaler also features a novel aerosol flow controller that ensures efficient and consistent delivery to the lungs, reducing dose to dose variation while minimizing oral deposition of the delivered drug.
About MAP Pharmaceuticals, Inc.
Located in Mountain View, California, MAP Pharmaceuticals is a specialty pharmaceutical company focused on the development of innovative therapies and inhalation delivery systems to treat a broad range of respiratory and systemic diseases. MAP’s lead product candidates are a proprietary formulation of inhaled DHE for the treatment of migraines and a proprietary formulation of budesonide for the treatment of asthma in both pediatric and adult populations. Additional information about MAP Pharmaceuticals can be found on our website at http://www.mappharma.com .
MAP Pharmaceuticals, Inc.
CONTACT: Lisa Johnson of MAP Pharmaceuticals, Inc., ljohnson@mappharma.com
Web site: http://www.mappharma.com//
